Elbasvir

DRUG12 trials

Conditions

Chronic Hepatitis CChronic Hepatitis C InfectionHepatic InsufficiencyHepatitis CHepatitis C VirusHepatitis, Viral, HumanRenal Impairment

Phase 1

Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)

CompletedNCT01532973

Merck Sharp & Dohme LLCHepatitis, Viral, Human

Start: 2012-02-16End: 2013-05-17Updated: 2018-07-17

The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)

CompletedNCT01797536

Merck Sharp & Dohme LLCHepatic Insufficiency

Start: 2013-03-06End: 2014-08-20Updated: 2018-10-25

The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)

CompletedNCT01937975

Merck Sharp & Dohme LLCChronic Hepatitis C, Renal Impairment

Start: 2013-09-06End: 2013-12-17Updated: 2019-06-12

Phase 2

A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)

CompletedNCT01717326

Merck Sharp & Dohme LLCHepatitis C

Start: 2013-02-07End: 2015-05-06Updated: 2021-02-05

Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)

CompletedNCT01932762

Merck Sharp & Dohme LLCHepatitis C

Start: 2013-10-01End: 2014-12-04Updated: 2021-02-04

Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)

CompletedNCT02092350

Merck Sharp & Dohme LLCHepatitis C Virus

Start: 2014-03-17End: 2015-09-02Updated: 2018-09-24

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)

CompletedNCT02115321

Merck Sharp & Dohme LLCChronic Hepatitis C

Start: 2014-05-09End: 2015-06-16Updated: 2019-06-26

Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)

CompletedNCT02203149

Merck Sharp & Dohme LLCHepatitis C

Start: 2014-08-01End: 2016-05-16Updated: 2018-09-24

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)

CompletedNCT02332720

Merck Sharp & Dohme LLCHepatitis C

Start: 2015-01-28End: 2017-05-03Updated: 2019-07-30

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)

CompletedNCT02332707

Merck Sharp & Dohme LLCHepatitis C

Start: 2015-01-22End: 2016-12-06Updated: 2019-07-23

Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)

CompletedNCT02601573

Merck Sharp & Dohme LLCHepatitis C

Start: 2016-01-05End: 2017-01-06Updated: 2019-08-13

Unknown Phase

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions

CompletedNCT02333292

Valme University HospitalChronic Hepatitis C Infection

Start: 2014-12-31End: 2017-06-30Updated: 2022-06-29

Journal of Antimicrobial Chemotherapy2023-09-064 citations

Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV‐infected people on opioid agonist therapy

Journal of Viral Hepatitis2021-03-15

Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study

Clinical and Translational Gastroenterology2019-03-2814 citations

Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.

2019-03-0843 citations

Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.

2019-01-258 citations

Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3

Clinical Therapeutics2018-04-255 citations

Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial

Hepatology2018-02-2325 citations

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.

2018-01-1736 citations

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C‐SCAPE study

Journal of Viral Hepatitis2017-11-2030 citations

Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection

Hepatology Communications2017-08-229 citations

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.

2017-08-1018 citations

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.

2017-08-1012 citations

Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.

2017-05-3057 citations

Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment‐naïve, noncirrhotic <scp>HCV</scp> genotype 3‐infected patients

Journal of Viral Hepatitis2017-05-0417 citations

Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.

2017-02-1159 citations

Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis

Canadian Journal of Gastroenterology and Hepatology2017-01-015 citations

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.

2016-11-2160 citations

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

2015-10-05492 citations

Susceptibilities of Genotype 1a, 1b, and 3 Hepatitis C Virus Variants to the NS5A Inhibitor Elbasvir

Antimicrobial Agents and Chemotherapy2015-08-2576 citations

High Efficacy Rates with Grazoprevir Plus Elbasvir in HCV Monoinfection and HCV/HIV Coinfection

MD Conference Express2014-12-01

2 more papers not shown

Elbasvir

Sponsors

Conditions

Phase 1

Phase 2

Unknown Phase

Related Papers